XLRN - Acceleron Pharma Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
51.61
-0.23 (-0.44%)
At close: 4:00PM EDT

51.30 -0.31 (-0.61%)
After hours: 4:11PM EDT

Stock chart is not supported by your current browser
Previous Close51.84
Open51.58
Bid0.00 x 800
Ask0.00 x 1200
Day's Range50.52 - 51.75
52 Week Range32.53 - 59.59
Volume120,622
Avg. Volume351,366
Market Cap2.374B
Beta (3Y Monthly)1.81
PE Ratio (TTM)N/A
EPS (TTM)-2.47
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est59.64
Trade prices are not sourced from all markets
  • Business Wire2 days ago

    Acceleron to Host Pulmonary Arterial Hypertension Research and Development Deep Dive Event on November 16, 2018 in New York City

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced it will webcast a live presentation from its Pulmonary Arterial Hypertension (PAH) Research and Development Deep Dive event on Friday, November 16, 2018. The meeting will feature presentations from leading PAH clinicians and researchers along with Acceleron senior management, who will discuss the current PAH treatment landscape and the importance of BMP signaling—a molecular pathway fundamental to all forms of the disease. The Company will highlight its latest preclinical research on sotatercept, its lead product candidate in PAH, which will have been presented at the American Heart Association Scientific Sessions on November 10-12, 2018.

  • 3 Top Small-Cap Stocks to Buy Right Now
    Motley Fool14 days ago

    3 Top Small-Cap Stocks to Buy Right Now

    Sometimes great stocks come in small packages.

  • Business Wire21 days ago

    Acceleron Announces Presentations on ACE-083 at the 23rd International Annual Congress of the World Muscle Society

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced plans to deliver poster presentations on ACE-083 from Part 1 of each its ongoing Phase 2 trials in patients with facioscapulohumeral muscular dystrophy (FSHD) and Charcot-Marie-Tooth disease (CMT) at the 23rd International Annual Congress of the World Muscle Society to be held in Mendoza, Argentina, October 2-6, 2018.

  • ACCESSWIRE28 days ago

    Today's Research Reports on Trending Tickers: Acceleron Pharma and Tesaro

    NEW YORK, NY / ACCESSWIRE / September 20, 2018 / Wall Street posted mixed results on Wednesday as tech shares weakened and trade tensions continued to rise. The Dow Jones Industrial Average gained 0.61 ...

  • Benzinga29 days ago

    Analyst: Acceleron's Blood Disorder Candidate Luspatercept Has Blockbuster Potential

    Acceleron Pharma Inc (NASDAQ: XLRN ) has a rich pipeline that positions the stock for additional upside, according to Piper Jaffray. The Analyst Analyst Danielle Brill upgraded Acceleron from Neutral to ...

  • Motley Foollast month

    Here's Why Acceleron Pharma Rose 24% in August

    Mr. Market thinks the double-digit slide from July was overdone. He may be right.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of XLRN earnings conference call or presentation 2-Aug-18 9:00pm GMT

    Q2 2018 Acceleron Pharma Inc Earnings Call

  • Investor's Business Daily2 months ago

    Could Biotech Giant Celgene Join Tesla In The Private Markets?

    Biotech giant Celgene could go private at 120 per share, an analyst suggested Wednesday after similarly sized electric-car maker Tesla confirmed it's discussing the possibility.

  • Here's Why Acceleron Pharma Inc. Lost 10.2% in July
    Motley Fool2 months ago

    Here's Why Acceleron Pharma Inc. Lost 10.2% in July

    The pharma company saw its share price adjusted after a huge gain at the end of June.

  • Benzinga2 months ago

    The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...

  • Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates
    Zacks2 months ago

    Acceleron Pharma (XLRN) Reports Q2 Loss, Tops Revenue Estimates

    Acceleron (XLRN) delivered earnings and revenue surprises of 1.56% and 7.94%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Acceleron: 2Q Earnings Snapshot

    On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 63 cents. The results surpassed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment ...

  • Business Wire2 months ago

    Acceleron Reports Second Quarter 2018 Operating and Financial Results

    – MEDALIST and BELIEVE Phase 3 trials met all primary and key secondary endpoints –

  • Benzinga3 months ago

    Acceleron Pharma Q2 Earnings Preview

    Acceleron Pharma (NASDAQ: XLRN ) releases its next round of earnings Thursday. Here's Benzinga's essential guide to Acceleron Pharma's Q2 earnings report. Earnings and Revenue Based on management's projections, ...

  • Business Wire3 months ago

    Acceleron to Webcast Second Quarter 2018 Operating and Financial Results on August 2, 2018

    Acceleron Pharma Inc. (XLRN) today announced it will host a webcast and conference call on Thursday, August 2, 2018 at 5:00 p.m. EDT to discuss its second quarter 2018 operating and financial results. The webcast will be accessible under "Events & Presentations" in the Investors/Media page of the company's website at www.acceleronpharma.com. The archived webcast will be available for replay on the Acceleron website approximately two hours after the event.

  • What Analysts Recommend for Celgene ahead of Its Q2 2018 Results
    Market Realist3 months ago

    What Analysts Recommend for Celgene ahead of Its Q2 2018 Results

    On July 9, Celgene (CELG) and Acceleron Pharma announced their results from the Phase 3 BELIEVE trial. Celgene and Acceleron conducted the Phase 3 BELIEVE trial to evaluate the safety and efficacy of luspatercept and the best supportive care compared to a placebo and the best supportive care for the treatment of adult individuals with transfusion-dependent beta thalassemia.

  • ACCESSWIRE3 months ago

    Free Pre-Market Technical Recap on Genesis Healthcare and Three Additional Healthcare Stocks

    On Tuesday, July 17, 2018, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Six out of nine sectors ended Tuesday's trading session in bullish territories. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Healthcare equities this morning: Brookdale Senior Living Inc. (NYSE: BKD), Envision Healthcare Corp. (NYSE: EVHC), Genesis Healthcare Inc. (NYSE: GEN), and Acceleron Pharma Inc. (NASDAQ: XLRN).

  • Benzinga3 months ago

    Morgan Stanley Downgrades Acceleron As Valuation Reaches Price Target

    Acceleron Pharma Inc (NASDAQ: XLRN) shares have gained about 39 percent since June 28 in reaction to positive Phase 3 study results for its luspatercept in low-to intermediate-risk myelodysplastic syndromes. The rally sent Morgan Stanley analyst Matthew Harrison to the sidelines. Acceleron's luspatercept data is strong, positioning the company for a filing in the first half of 2019, but there is possibility of limited near-term upside, Harrison said in a Friday morning note.

  • Business Wire3 months ago

    Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

    Acceleron Pharma Inc. (XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that the United States Food and Drug Administration (FDA) has granted orphan drug designation for ACE-083, the Company’s locally acting “Myostatin+” muscle agent, for the treatment of patients with facioscapulohumeral muscular dystrophy (FSHD). “We are pleased to receive orphan drug designation for ACE-083, which has shown the potential to address an area of high unmet medical need,” said Robert K. Zeldin, M.D., Chief Medical Officer of Acceleron.

  • Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More
    Zacks3 months ago

    Biotech Stock Roundup: BIIB's Gain on Alzheimer's Data, Regulatory Updates & More

    Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.

  • Celgene, Acceleron Report Positive Data on Thalassemia Drug
    Zacks3 months ago

    Celgene, Acceleron Report Positive Data on Thalassemia Drug

    Celgene (CELG) and partner Acceleron Pharma report positive results on luspatercept from a late-stage study. This is the second positive phase III study for the candidate.

  • Benzinga3 months ago

    Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 9) Aerpio Pharmaceuticals Inc (NASDAQ: ARPO ) Arrowhead Pharmaceuticals ...